Loading company…
Regenverse develops human-derived stem cells for regenerative medicine and neurological research.
Founded in 2019, Guangzhou Regenverse Therapeutics develops human-induced pluripotent stem cells and human-derived neural stem cells, including several neuron types. Its products are intended for regenerative medicine and neurological research, serving research institutions, pharmaceutical companies and biotech firms. The company is based in Guangzhou, China. In May 2025, it raised CNY 100 million in pre-Series A funding for IND filing and its iDA-001 Parkinson's disease cell therapy pipeline.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in